SUN PHARMACEUTICAL INDUSTRIES LIMITED Patent applications |
Patent application number | Title | Published |
20160081972 | PARENTERAL DOSAGE FORM OF AMIODARONE - The present invention relates to a stable, sterile, ready to administer parenteral dosage form of amiodarone or its pharmaceutically acceptable salt. Particularly, the present invention provides a stable, sterile, ready to administer parenteral dosage form of amiodarone comprising an aqueous solution comprising amiodarone or its pharmaceutically acceptable salt, an acid, and a polyol, wherein the pH of the solution is in the range of about 2.0 to 4.0, wherein the solution is filled in a plastic container and wherein the solution is free of a solubilizer. | 03-24-2016 |
20160058663 | PERFUSION DOSAGE FORM - The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. | 03-03-2016 |
20150329526 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR SALTS THEREOF - The present invention provides a process for the preparation of pazopanib of Formula Ia or salts, and intermediates thereof. | 11-19-2015 |
20150313848 | PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN - The present invention relates to stable pharmaceutical compositions comprising rifaximin and processes for their pre-paration. | 11-05-2015 |
20140213984 | OCTREOTIDE INJECTION - The present invention provides a sterile solution comprising octreotide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in multiple daily doses and further being adapted to provide multiple portions of the said solution, while the reservoir remains sterile. | 07-31-2014 |
20130030186 | PROCESS FOR PREPARING SULPHOXIDE COMPOUNDS - A process for the enantioselective synthesis of a sulphoxide of a compound of Formula I or a pharmaceutically acceptable salt thereof in the form of a single enantiomer or in an enantiomerically enriched form | 01-31-2013 |
20100172982 | SUSTAINED RELEASE FORMULATIONS OF DIVALPROEX SODIUM - A sustained release tablet formulation comprising an inner phase comprising a mixture of divalproex or its pharmaceutically acceptable salt and a hydrophobic agent, and an outer phase comprising a hydrophilic polymer, wherein the hydrophobic agent is present in amount ranging from 6.3% to about 8.3% by weight of the formulation. | 07-08-2010 |
20100172972 | ENTERIC COATED PHARMACEUTICAL COMPOSITIONS - The present invention relates to an enteric coated pharmaceutical composition comprising a core in the from of pellets comprising a therapeutically effective amount of duloxetine or its pharmaceutically acceptable salt, the pellets having a size between 700 to 1000 μm; a separating layer surrounding the core, comprising one or more pharmaceutically acceptable film-forming polymers and pharmaceutically acceptable excipient(s), the separating layer being present in an amount ranging from about 5% to about 20% by weight of the composition, and an enteric layer surrounding the separating layer comprising about 8% to about 25% by weight of the composition of poly(methacrylic acid, ethyl acrylate) (1:1) neutralized to a pH of about 5.0, wherein the enteric coated pharmaceutical composition, when administered orally to human subjects on an empty stomach, provides a maximum plasma concentration of duloxetine ranging from about 25 ng/ml to about 45 ng/ml, occurring from about 5 to 7 hours. | 07-08-2010 |
20090123556 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS - The present invention provides a sustained release microsphere composition comprising | 05-14-2009 |
20090123541 | Pharmaceutical Composition - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 05-14-2009 |